AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q1 2018 Earnings Presentation

41 slides from AMAG Pharmaceuticals's earnings presentation, May 3, 2018

  1. Slide 1: AMAG Pharmaceuticals Q1-2018 Financial Results and Corporate Update

    AMAG Pharmaceuticals Q1-2018 Financial Results and Corporate Update May 3, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, ex

  3. Slide 3: Today's Agenda

    Today’s Agenda 3 Q1-2018 Highlights1 4 Key Priorities and Closing Remarks 3 Q1-2018 Financial Overview 5 Q&A 2 Product Portfolio Update

  4. Slide 4: Q1-2018 Highlights: Strong Execution

    Strong Execution Makena, $90.0 CBR, $29.0 Intrarosa, $2.2 Feraheme /MuGard, $25.2 Q1-2018 revenue up 5% year-over-year $M Q1-2018 Total revenue $146.4  Ended Q1-2018 with >$370M in cash and investments  Received FDA approval for Makena subcutaneous auto-injector  Received FDA approval for broad F

  5. Slide 5: Product Portfolio Update

    Product Portfolio Update •Makena® • Feraheme® • Intrarosa® • Cord Blood Registry® • Bremelanotide 5

  6. Slide 6: Makena: Solid Market Share and Revenue Growth

    Makena: Solid Market Share and Revenue Growth 6 M A T E R N A L H E A L T H : M A K E N A 1 Company estimates Makena market share based on distributor dispensing data and all other market share based on physician market research data conducted by AMAG. 2 Based on 140,000 patients, >16 injections/pat

  7. Slide 7: Makena SC Auto-injector Launched March 26, 2018

    Efficient Discreet Administration friendly Makena SC Auto-injector Launched March 26, 2018 M A T E R N A L H E A L T H : M A K E N A    Subcutaneous injection Intramuscular injection First Patient Injected March 28 7

  8. Slide 8: Strong Early Progress Converting to SC Auto-injector

    Strong Early Progress Converting to SC Auto-injector 8 M A T E R N A L H E A L T H : M A K E N A Week % o f Ma ke n a C ar e Con n ec tion E n ro llm en ts SC auto-injector accounted for 47% of Makena Care Connection enrollments in the most current week 14.0% 31.0% 38.0% 47.0% 86.0% 69.0% 62.0% 53.0

  9. Slide 9: SC Auto-injector Expected to be Used in Majority of Treated Patients

    SC Auto-injector Expected to be Used in Majority of Treated Patients Assuming Price Parity1 M A T E R N A L H E A L T H : M A K E N A 6% 2% 2% 8% 83% ‘Future’ Prescribing3 (HCPs, n=20) Q1-17 Prescribing2 (HCPs, n=30) 8% 18% 67% N/A N/A Makena SC4 Makena IM Generic HPC single-dose vial4 Compounded IM

  10. Slide 10: Product Portfolio Update

    Product Portfolio Update • Makena® •Feraheme® • Intrarosa® • Cord Blood Registry® • Bremelanotide 10

  11. Slide 11: Q1-2018 Feraheme Results Impacted by Saline Shortage

    Q1-2018 Feraheme Results Impacted by Saline Shortage 11 $25.9 $25.1 Q1-2017 Q1-2018 Feraheme Revenue1 1 Represents Feraheme revenue only. Excludes MuGard revenue as reported on financial statements. 2 HCP market research conducted by AMAG.  Temporary shortage of saline solution caused by hurricane

  12. Slide 12: Growing Share through Clinical Differentiation and New Broad Label

    Growing Share through Clinical Differentiation and New Broad Label 121 AMAG estimates market share using IQVIA (formerly IMS) data and internal analytics. Feraheme Market Share1 I V I R O N D E F I C I E N C Y A N E M I A : F E R A H E M E 11.8% 10.2% 10.7% 12.3% Dec-17 Jan-18 Feb-18 Mar-18 Saline s

  13. Slide 13: Feraheme Broad IDA Label Approved

    FERAHEME® is the only IV iron demonstrating effective treatment for IDA in adult patients with 1g of iron across 2 fifteen-minute infusions 3-8 days apart 13 Feraheme Broad IDA Label Approved February 2, 20181 Strong Data in New Broad IDA Feraheme Label… I V I R O N D E F I C I E N C Y A N E M I A :

  14. Slide 14: Data Comparing Phosphate Levels Over Time

    14 Data Comparing Phosphate Levels Over Time I V I R O N D E F I C I E N C Y A N E M I A : F E R A H E M E

  15. Slide 15: Data Comparing Phosphate Levels Over Time

    15 Data Comparing Phosphate Levels Over Time Published in Am J Hematol I V I R O N D E F I C I E N C Y A N E M I A : F E R A H E M E

  16. Slide 16: Product Portfolio Update

    Product Portfolio Update • Makena® • Feraheme® •Intrarosa® • Cord Blood Registry® • Bremelanotide 16

  17. Slide 17: Intrarosa is Differentiated from Estrogen Therapies

    Non-estrogen treatment2 Unique safety profile (no boxed warning) Differentiated MOA Intrarosa is Differentiated from Estrogen Therapies1 W O M E N ’ S H E A L T H : I N T R A R O S A    1 Market research sponsored by AMAG and conducted by Roscow Market Research. 2 Intrarosa is converted by enzyme

  18. Slide 18: Good Progress Since Launch

    Good Progress Since Launch TRx’s written since launch1 ~50,000 HCP prescribers since launch1 ~6,600 Commercial lives covered (unrestricted)2 74% Total week ending market share1 2.8% W O M E N ’ S H E A L T H : I N T R A R O S A 1 Based on IQVIA (formerly IMS) data. 2 MMIT data adjusted for non-repor

  19. Slide 19: HCP Prescribing and Market Share Continue to Increase

    HCP Prescribing and Market Share Continue to Increase 0 500 1,000 1,500 2,000 2,500 3,000 Monthly Rx Volume1 TRx NRx Linear (TRx) Linear (NRx) Numbe r of Sc ri p ts 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% Monthly Market Share1 TRx NRx Linear (TRx) Linear (NRx) W O M E N ’ S H E A L T H : I N T R A R

  20. Slide 20: Intrarosa Expected to Expand Prescriptions for Dyspareunia

    1 Market research sponsored by AMAG and conducted by Roscow Market Research in 2017. 2 TXMD 004 PDUFA date May 29, 2018. Intrarosa Expected to Expand Prescriptions Written for Dyspareunia by 16% and Take >25% Share1 W O M E N ’ S H E A L T H : I N T R A R O S A Fielded in February 2017 (mean %) With

  21. Slide 21: Dyspareunia: 90% of Affected Women Not on Rx Therapy

    21 Dyspareunia: 90% of Affected Women Not on Rx Therapy W O M E N ’ S H E A L T H : I N T R A R O S A 20M women in U.S. suffer from dyspareunia, a symptom of VVA1 +18 Million2 U.S. women with dyspareunia not on prescription therapy ~1.7 Million2 U.S. women with dyspareunia treated with prescription

  22. Slide 22: Key Intrarosa Growth Drivers

    Key Intrarosa Growth Drivers Launch Priority 1 Launch Priority 2 Launch Priority 3 Create affordable access for all patients Increase market awareness Increase HCP prescribing Launch Priority 4 Launch Priority 5 Make Intrarosa the 1st choice treatment among HCPs Educate potential patients about cond

  23. Slide 23: First Unbranded Consumer Social Media Campaign Activated

    First Unbranded Consumer Social Media Campaign Activated “press pause” W O M E N ’ S H E A L T H : I N T R A R O S A 23

  24. Slide 24: Product Portfolio Update

    Product Portfolio Update • Makena® • Feraheme® • Intrarosa® • Cord Blood Registry® • Bremelanotide 24

  25. Slide 25: Cord Blood Registry Returned to Growth

    Returned to Growth 25 3,399 3,802 Q1-2017 Q1-2018 M A T E R N A L H E A L T H : C O R D B L O O D R E G I S T R Y 12% Growth in New Family Enrollments Strong commercial execution driving new enrollments Two-thirds of revenue driven by growing, recurring annual storage fees $26.9 $29.0 Q1-2017 Q1-201

  26. Slide 26: Product Portfolio Update

    Product Portfolio Update • Makena® • Feraheme® • Intrarosa® • Cord Blood Registry® •Bremelanotide 26 © 2018 AMAG Pharmaceuticals, Inc. All rights reserved.

  27. Slide 27: Bremelanotide: Significant Opportunity in Area of High Unmet Need

     Investigational product to treat hypoactive sexual desire disorder (HSDD) in pre- menopausal women  Self-administered auto-injector pen used in anticipation of sexual activity  Novel mechanism of action: melanocortin receptor agonist (MCR4)  Two Phase 3 studies met co-primary, pre-specified end

  28. Slide 28: Significant Market Opportunity

    Treated (Rx) Presented to HCP, but not Rx treated Have not discussed HSDD with an HCP 0.1M3 0.9M3 4.8M Significant Market Opportunity1 28 1 If regulatory approval is received. 2 Shifren et al, Sexual Problems and Distress in United States Women; Obstetrics & Gynecology, Vol. 112, No. 5, November 200

  29. Slide 29: HSDD Education and Awareness Campaign Underway

    HSDD Education and Awareness Campaign Underway https://knowhsdd.com W O M E N ’ S H E A L T H : B R E M E L A N O T I D E HSDD: Breaking the Silence ACOG Annual Meeting April 27-30, 2018 Austin, TX 29

  30. Slide 30: Financial Overview

    Financial Overview 30

  31. Slide 31: Strong Financial Results While Investing in the Future

    $139.5 $146.4 ($40.0) ($44.9) Q1-2017 Q1-2018 5% Strong Financial Results While Investing in the Future 31 GAAP Product Revenue and Operating Loss Makena revenue CBR revenueFeraheme/MuGard revenue GAAP operating lossIntrarosa revenue $M

  32. Slide 32: Strong Financial Results: Non-GAAP Adjusted EBITDA

    Strong Financial Results While Investing in the Future 1 See slide 39 for a reconciliation of GAAP to non-GAAP financials. Going forward, AMAG will only present GAAP revenue, as historically the only difference between GAAP and non-GAAP revenue was an adjustment to CBR purchase accounting related to

  33. Slide 33: Strong Cash Flow Generation

    Strong Cash Flow Generation Cash, cash equivalents and investments $329 $371 Principal debt outstanding: Convertible senior notes (2.5%) due 2019 $ 21 $ 21 Convertible senior notes (3.25%) due 2022 320 320 Senior notes (7.785%) due 2023 475 475 Total debt outstanding $816 $816 3/31/1812/31/17 $M 33

  34. Slide 34: Increased 2018 Financial Guidance

    Increased 2018 Financial Guidance1 Total revenue $500 - $560 $540 - $580 GAAP operating loss ($147) - ($117) ($128) - ($108) Non-GAAP adjusted EBITDA $100 - $130 $120 - $140 Previous Updated $M 1 See slide 40 for a reconciliation of 2018 financial guidance. 34

  35. Slide 35: 2018 Key Priorities

    2018 Key Priorities Intrarosa  Continue to drive awareness and HCP prescribing Feraheme  Launch broad IDA label and grow market share Makena  Launch subcutaneous auto-injector and drive conversion Cord Blood Registry  Continue to grow new first-time enrollments Business Development  Build share

  36. Slide 36: AMAG Pharmaceuticals Q&A

    AMAG Pharmaceuticals Q&A May 3, 2018

  37. Slide 37: Appendix

    Appendix

  38. Slide 38: AMAG Product Portfolio Overview

     Treatment of iron deficiency anemia (IDA) in all eligible adult patients  The only FDA-approved therapy to reduce the risk of recurrent preterm birth in certain at-risk women  Candidate for the treatment of severe preeclampsia  An investigational product for the treatment of hypoactive sexual d

  39. Slide 39: Reconciliation of GAAP to Non-GAAP Financial Results

    Reconciliation of GAAP to Non-GAAP Financial Results 39 $M Q1-2017 Q1-2018 GAAP operating loss ($40.0) ($44.9) Purchase accounting adjustments related to CBR deferred revenue 1.4 -- Depreciation and intangible asset amortization 27.2 57.3 Non-cash inventory step-up adjustments 0.7 2.2 Stock-based co

  40. Slide 40: Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance

    Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance 40 $M Previous Updated GAAP Operating loss ($147) – ($117) ($128) – ($108) Depreciation & intangible asset amortization 200 200 Stock-based compensation 23 24 Non-cash inventory step up and adjustments to contingent consideration 4 4 Acquire

  41. Slide 41: All rights reserved. AMAG Pharmaceuticals Q1-2018 Financial Results and

    © 2018 AMAG Pharmaceuticals, Inc. All rights reserved. 41 AMAG Pharmaceuticals Q1-2018 Financial Results and Corporate Update May 3, 2018

Amag Pharmaceuticals — Q1 2018 Earnings Presentation on 6ix